CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 47 enrolled
Drug / intervention
LY2495655 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01341470
NCT01341470Phase 1Completed
CompareCT.gov

A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2495655 in Japanese Subjects

Eli Lilly and Company·interventional·Posted Apr 25, 2011·Updated Jun 17, 2019

In Brief

A Phase 1 clinical trial evaluating LY2495655 and Placebo for Healthy Volunteer. Completed, enrolled 47 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of LY2495655 administered subcutaneously and intravenously in Japanese subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2011
Enrollment StartMay 1, 2011
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.2 years ago

Interventions

LY2495655drug

administered intravenously or subcutaneously

Placebodrug

administered intravenously or subcutaneously